## **Product** Data Sheet

## **Immepip**


Cat. No.: HY-101321 CAS No.: 151070-83-6

Target: Histamine Receptor

Pathway: GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

Description	Immepip is a H3 agonist. Immepip can reduce cortical histamine release. Immepip can be used for the research of neurological diseases <sup>[1]</sup> .	
In Vivo	Immepip (i.p.; 5, $10 \text{ mg/kg}$ ) markedly reduces cortical histamine release, but only weakly promotes sleep in the rat <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Sprague-Dawley rats <sup>[1]</sup>
	Dosage:	5, 10 mg/kg
	Administration:	Intraperitoneally
	Result:	Significantly modulated brain histamine release and slight, albeit significant, decreased in sleep onset latency.

## **REFERENCES**

[1]. Yves Lamberty, et al. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol Res. 2003 Aug;48(2):193-8.

[2]. Yves Lamberty, et al. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol Res. 2003 Aug;48(2):193-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA